Table 9. Cost per responder and patient in remission–per member per month (ABA-1L vs. ABA-2L+).

	Cost per health gaina (ABA-1L)	Cost per health gaina (ABA-2L+)	±10% incremental cost for ABA-2L+b	Difference in costs (ABA-1L - ABA-2L+)
Primary endpoint: cost per responding patient (JPY)
ACR50	865,509	988,333	889,500; 1,087,166	-122,824
Secondary endpoints: cost per patient in remission (JPY)
CDAI	364,425	628,939	566,045; 691,833	-264,514
SDAI	364,425	628,939	566,045; 691,833	-264,514

1L, first line; 2L+, second or later line; ABA, abatacept; ACR50, American College of Rheumatology response of at least 50% improvement; CDAI, Clinical Disease Activity Index; SDAI, Simplified Disease Activity Index.

^aTotal costs in ABA-1L or ABA-2L+ divided by the number of ACR responders or patients in CDAI or SDAI remission.

^bCrude sensitivity analysis where the incremental costs for ABA-2L+ were increased/decreased by 10%.